SILO PHARMA, INC.: 10-Q filed 2020-05-12
What SILO PHARMA, INC. reported in its quarterly report filed 2020-05-12 (fiscal Q1 2020): 23 published measures, 47 facts as tagged in accession 0001213900-20-011867.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-05-12
- Fiscal period
- fiscal Q1 2020
- Accession
- 0001213900-20-011867 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SILO PHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 403,817 | USD | |
| At 2019-12-31 | 493,845 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -261,769 | USD | |
| At 2019-12-31 | -22,892 | USD | |
| At 2019-03-31 | 292,669 | USD | |
| At 2018-12-31 | 407,442 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 9,143 | USD | |
| At 2019-12-31 | 111,752 | USD | |
| At 2019-03-31 | 177,346 | USD | |
| At 2018-12-31 | 336,679 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -238,877 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -123,523 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -117,609 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -149,524 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 294 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 15,000 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -9,809 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -2,894,681 | USD | |
| At 2019-12-31 | -2,655,804 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 30,578 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 30,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -159,358 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -174,565 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 403,817 | USD | |
| At 2019-12-31 | 493,845 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 82,500 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 454 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 265,586 | USD | |
| At 2019-12-31 | 116,737 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 159,568 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 174,565 | USD | 90 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 155,913 | USD | |
| At 2019-12-31 | 156,366 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 210 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 23,604,207 | shares | |
| At 2019-12-31 | 23,604,207 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 2,630,551 | USD | |
| At 2019-12-31 | 2,630,551 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 29,367 | USD | |
| At 2019-12-31 | 16,333 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -238,877 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -123,523 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 17,038 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 12,289 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -79,519 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 51,042 | USD | 90 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -453 | USD | 91 |
Inspect the source
- Entity
- SILO PHARMA, INC. / CIK 0001514183
- Captured
- 2026-09-20T09:13:20.337Z
- SEC response SHA-256
b55b01ff5b31c52a933a54029f5fe837eae02333bd43de16acad37f51e3b67db
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001514183.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))